DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/j8zj74/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer Drug Pipeline Update" report to their offering.
There are today 367 companies plus partners developing 406 drugs targeting pancreatic cancer in development. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 132 drugs. Pancreatic Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 342 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer.
To date 332 out of the 334 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 74 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Includes more than 367 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & Synonyms
Lists commercial, generic and code names for drugs.
This Drug Pipeline Update contains 406 drugs in development for the treatment of pancreatic cancer. In addition there are suspended and ceased drugs.
Pipeline Breakdown According to Number of Drugs
- Marketed - 15
- Registered - 1
- Pre-registration - 1
- Phase III - 25
- Phase II - 135
- Phase I - 103
- Preclinical - 119
- No Data - 7
- Suspended - 1
Ceased - 132
For more information visit http://www.researchandmarkets.com/research/j8zj74/pancreatic_cancer